(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
5 June 2014 (05.06.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/085596 A1

(51) International Patent Classification:
A61K 39/00 (2006.01) *C07K 16/00* (2006.01)
A61K 39/395 (2006.01) *C07K 16/24* (2006.01)

(21) International Application Number:
PCT/US2013/072243

(22) International Filing Date:
27 November 2013 (27.11.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/731,294 29 November 2012 (29.11.2012) US
61/786,472 15 March 2013 (15.03.2013) US

(71) Applicant: **BAYER HEALTHCARE LLC** [US/US]; 100 Bayer Boulevard, Whippany, NJ 07981-0915 (US).

(72) Inventors: **ZHAO, Xiao-Yan**; 5075 Anaheim St., Union City, CA 94587 (US). **WANG, Zhuozhi**; 1388 Broadway, Unit 383, Millbrae, CA 94030 (US). **GU, Jian-Ming**; 3272 Vale Lane, Lafayette, CA 94549 (US). **KIM, Ji-Yun**; 1168 Besito Ave., Berkeley, CA 94705 (US). **BAUZON, Maxine**; 1033 Park Street, Hercules, CA 94547 (US). **MURPHY, John, E.**; 1139 The Alameda, Berkeley, CA 94707 (US). **MCLEAN, Kirk**; 54 Tara Road, Orinda, CA 94563 (US). **JIN, Fang**; 353 Woodward Street, Waban, MA 02468 (US). **MARQUARDT, Tobias**; Viktoriastr. 81, 42115 Wuppertal (DE). **WANG, Xinquan**; Beijing (CN). **WILMEN, Andreas**; Arndtstr. 5, 50676 Cologne (DE).

(74) Agent: **HIGHLANDER, Steven L.**; Parker Highlander PLLC, 1120 S. Capital of Texas Highway, Building One, Suite 200, Austin, TX 78746 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: MONOCLONAL ANTIBODIES AGAISNT ACTIVATED PROTEIN C (aPC)

Figure 1



(57) Abstract: Provided herein are antibodies, antigen-binding antibody fragments (Fabs), and other protein scaffolds, directed against human activated Protein C (aPC) with minimal binding to its zymogen Protein C (PC). Moreover, these aPC binding proteins could potentially block the anti-coagulant activity of aPC to induce coagulation. Therapeutic uses of these binders are described herein as are methods of panning and screening specific antibodies.

WO 2014/085596 A1